The lead candidate from DynamiCure’s anti-CD93 program, DCBY02 targets a wide range of metastatic solid tumors Phase 1 trial aims to assess the safety and anti-tumor activity of... read more →
DCBY02 to be assessed in patients with advanced or metastatic solid tumors across dose-escalation and dose-expansion parts of a Phase 1 clinical study Waltham, MA — August 22, 2022 —... read more →